Janssen’s teclistamab gets CMA from European Commission
Teclistamab is the first bispecific antibody worldwide to be approved for patients with relapsed and refractory multiple myeloma
Read MoreTeclistamab is the first bispecific antibody worldwide to be approved for patients with relapsed and refractory multiple myeloma
Read MoreIn 2019, there were over 850,000 people with dementia in the UK, representing one in every 14 people aged 65 and over
Read MoreThe phase 2/3 trial results showed that the vaccine was effective in protecting children
Read MoreUsing the system, the researchers are able to divide DNA and RNA from an already extracted clinical sample into as many as 100,000 microscopic individual reactions
Read More




PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
